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Purpose of these guidelines
The Clinical Practice Council of the Society for Vascular
Surgery charged a writing committee with the task of updat-
ing practice guidelines, initally published in 2003, for sur-
geons and physicians who are involved in the preoperative,
operative, and postoperative care of patients with abdominal
aortic aneurysms (AAA).1 This article is an executive summary
of the main practice guidelines document and provides rec-
ommendations for evaluating the patient, including risk of
aneurysm rupture and associated medical co-morbidities,
guidelines for selecting surgical or endovascular interven-
tion, intraoperative strategies, perioperative care, long-
term follow-up, and treatment of late complications.2
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880Decision making related to the care of patients with
AAA is complex. Aneurysms present with varying risks of
rupture, and patient-specific factors influence anticipated
life expectancy, operative risk, and the need to intervene.
Careful attention to the choice of operative strategy, as
influenced by anatomic features of the AAA, along with
optimal treatment of medical co-morbidities is critical to
achieving excellent outcomes. Moreover, appropriate post-
operative patient surveillance and timely intervention in the
case of a late complication is necessary to minimize subse-
quent aneurysm-related death or morbidity. All of these
clinical decisions are determined in an environment where
cost-effectiveness will ultimately dictate the ability to pro-
vide optimal care to the largest possible segment of the
population. Currently available clinical data sets have been
reviewed in formulating these recommendations. However,
an important goal of this document is to clearly identify those
areas where further clinical research is necessary.
Methodology and evidence
A comprehensive review of the available clinical evidence
in the literature was conducted in order to generate a concise
set of recommendations. The strength of any given recom-
mendation and the quality of evidence was scored based on
the GRADE system (Table).3 When the benefits of an inter-
vention outweighed its risks, or, alternatively, risks out-
weighed benefits, a strong recommendation was noted.
However, if benefits and risks were less certain, either because
of low quality evidence or because high quality evidence
suggests benefits and risks are closely balanced, a weak rec-
ommendation was recorded. The quality of evidence that
formed the basis of these recommendations was scored as
high, moderate, or low. Not all randomized controlled trials
are alike and limitations may compromise the quality of their
evidence. In addition, if there is a large magnitude of effect,
the quality of evidence derived fromobservational studiesmay
be high. Thus, quality of evidence was scored as highwhen
additional research is considered very unlikely to change con-
fidence in the estimate of effect; moderate when further
research is likely to have an important impact on in the
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change the estimate of the effect.
GENERAL APPROACH TO THE PATIENT
History
Themedical history is helpful in determining the patient’s
risk of developing an AAA. Even in the absence of clinical
symptoms, knowledge of the risk factors for developing an
AAA may facilitate early diagnosis. The Aneurysm Detection
and Management Veterans Affairs Cooperative Study Group
(ADAM) trial found a number of factors to be associated with
increased risk forAAA: advanced age, greater height, coronary
artery disease (CAD), atherosclerosis, high cholesterol levels,
hypertension, and, in particular, smoking.4 An AAA is over
seven times more likely to develop in a smoker than a non-
smoker, with the duration of smoking, rather than total num-
ber of cigarettes smoked, being the key variable.5 Family
members are also at significant risk with 12% to 19% of those
undergoing aneurysm repair having a first-degree relativewith
an AAA.6 The risk for developing an AAA is lower in women,
African Americans, and diabetic patients. Risk factors for rup-
ture have also been identified, including female gender, large
initial aneurysm diameter, low forced expiratory volume in
one second (FEV1), current smoking history, and elevated
mean blood pressure.
Physical examination
Only 30% to 40% of aneurysms are noted on physical
examination, with detection dependant on aneurysm size and
limited by truncal obesity. An abdominal aneurysm may be
present in up to 85% of patients with a femoral artery aneu-
rysm and in up to 60% of those with a popliteal aneurysm. In
contrast, approximately 15% patients with an abdominal an-
Table. Criteria for strength of a recommendation and
grading quality of evidence
Strength of a Recommendation
Strong Benefits  Risks
Risks  Benefits
Weak Benefits  Risks
Quality of evidence precludes
accurate assessment of risks
and benefits
Grading Quality of Evidence
High Additional research is
considered very unlikely to
change confidence in the
estimate of effect
Moderate Further research is likely to
have an important impact
on the estimate of effect
Low Further research is very likely
to change the estimate of
the effect
Adapted from Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D,
Hylek EM, Phillips B, et al. Grading strength of recommendations and
quality of evidence in clinical guidelines. Chest 2006;129:174-81.eurysm have either a femoral or a popliteal artery aneurysm.Physical examination should include an assessment of femoral and
popliteal arteries in all patients with a suspected abdominal
aortic aneurysm.
Level of recommendation: Strong
Quality of evidence: High
Co-morbid disease
Coronary artery disease (CAD) is the leading cause of
early and late mortality after AAA repair. Chronic kidney
disease, chronic obstructive pulmonary disease (COPD),
and diabetes mellitus may also influence morbidity and
mortality. Accordingly, further evaluation is warranted and
optimization of perioperative status beneficial when any of
these conditions are present.
Cardiac disease
Preoperative evaluation of cardiac morbidity. A
substantial portion of patients with AAA have underlying
CAD and postoperative myocardial infarction (MI) carries
with it a substantially increased risk of death, as well as a
high risk for later cardiovascular events and death. Indeed,
while elective open surgical repair (OSR) can generally be
considered to carry a higher risk for a perioperative cardio-
vascular event than endovascular aortic aneurysm repair
(EVAR), the latter is associated with intermediate to high
cardiac risk in the range of 3% to 7%. Thus, it is critical to
minimize the risk of cardiac morbidity during the course of
OSR or EVAR for AAA.
In the absence of an active cardiac condition (unstable or
severe angina, recent MI 1 month, decompensated heart
failure, significant arrhythmia, or severe valvular heart disease),
further non-invasive testing is only indicated if it will change
management. Asymptomatic patients capable of a moderate
or high activity level (metabolic equivalent unit [MET] 4),
such as climbing stairs or a short run, generally do not benefit
from further testing. However, those patients who present
with three ormore cardiac risk factors (history of heart disease,
congestive heart failure, cerebral vascular disease, diabetes,
creatinine 2 mg/dL) and have an unknown or low activity
level (MET 4) may benefit from stress testing.
Noninvasive stress testing should be considered for patients with a
history of three or more clinical risk factor (ie, coronary artery
disease [CAD], congestive heart failure [CHF], cerebrovascular
accident [CVA], diabetes mellitus [DM], chronic renal
insufficiency [CRI]) and an unknown or poor functional capacity
(MET 4) who are undergoing EVAR or OSR, if it will change
management.
Level of recommendation: Strong
Quality of evidence: Moderate
Routine coronary revascularization by coronary artery by-
pass grafting (CABG) or percutaneous transluminal coronary
angioplasty (PTCA) prior to elective vascular surgery in pa-
tients with stable cardiac symptoms does not appear to signif-
icantly alter the risk of postoperativeMI or death or long-term
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larization is indicated for those patients who present with
acute ST elevation MI, unstable angina, or stable angina with
left main coronary artery or three-vessel disease, as well as
those patients with two-vessel disease that includes the proxi-
mal left anterior descending artery and either ischemia on
non-invasive testing or an ejection fraction of less than 0.50.
Perioperativemedicalmanagement of coronary artery
disease. Perioperative heart rate control with beta blockade
appears appropriate for patients with known cardiovascular
disease or at least one clinical risk factor, but should be started
days toweeks before elective surgerywith a target heart rate of
less than 65 beats per minute.7 Recent clinical data also
supports the notion that statins, alpha-2 agonists for periop-
erative control of hypertension, and calcium channel blockers
reduce perioperative cardiac morbidity and death.
Areas in Need of Further Research
● Improved strategies to identify patients at risk for postopera-
tive MI or cardiovascular related death.
Pulmonary disease. Between 7% and 11% of patients
with chronic obstructive pulmonary disease (COPD) have
an aneurysm and failure to optimize COPDmanagement is
associated with increased morbidity and mortality. If
COPD is severe, formal pulmonary consultation is recom-
mended for prediction of short- and long-term prognosis
and optimization of medical therapy. In general, smoking
cessation for at least two weeks prior to aneurysm repair can
be beneficial and administration of pulmonary bronchodi-
lators for at least two weeks prior to aneurysm repair is
recommended for patients with a history of symptomatic
COPD or abnormal pulmonary function studies.
Areas in Need of Further Research
● Perioperative management recommendations for patients with
preexistent pulmonary disease.
Renal impairment. Preoperative renal insufficiency is
known to be a risk factor for a poor outcome after open
aneurysm repair. To minimize deterioration in renal func-
tion among these patients, preoperative intravenous hydra-
tion is recommended and angiotensin-converting enzyme
inhibitors and angiotensin receptor antagonists should be
held the morning of surgery and restarted only after the
patient is euvolemic.8 Recent meta-analyses have not
identified a significant benefit from intraoperative use of
mannitol alone,9 but have found beneficial effects from
fenoldopam, particularly when administered at 0.1 g/
kg/min beginning at the initiation of surgery.10 Likewise,
patients at increased risk for contrast-induced nephropathy
(CIN) should be hydrated both prior (normal saline 1
ml/kg/h for six to 12 hours or D5W/sodium bicarbonate154 meq/L, 3 mL/kg for one hour) and after (normal
saline 1 ml/kg/h for six to 12 hours or D5W/sodium
bicarbonate 154 meq/L, 1 mL/kg for six hours) receipt of
a contrast dye load as in EVAR. While fenoldapam, dopa-
mine, theophylline, or calcium channel blockers do not
appear to be beneficial in preventing CIN, N-acetylcysteine
and ascorbic acid may be of benefit.11 The incidence of
CIN appears to be lower with iodixanol (Visipaque) and
iopamidol (Isovue-370) than with iohexol (Omnipaque).
Use of CO2 gas as an alternate imaging agent may be
considered. Gadolinium-based contrast agents carry an in-
creased risk of nephrogenic systemic fibrosis among pa-
tients with severe renal insufficiency.
Angiotensin-converting enzyme inhibitors and angiotensin receptor
antagonists should be held the morning of surgery and restarted
after the patient is euvolemic.
Level of recommendation: Strong
Quality of evidence: Moderate
Preoperative hydration is recommended for patients with renal
insufficiency prior to aneurysm repair.
Level of recommendation: Strong
Quality of evidence: Moderate
Pre- and post procedure hydration with normal saline or 5%
dextrose/sodium bicarbonate is recommended for patients at
increased risk of contrast induced nephropathy.
Level of recommendation: Strong
Quality of evidence: Moderate
Areas in Need of Further Research
● Perioperative management recommendations for patients with
renal insufficiency.
● Optimal preoperative hydration regimen for patients with re-
nal insufficiency undergoing OSR.
● Recommendations to reduce the risk of contrast-induced ne-
phropathy among patients with renal insufficiency undergoing
EVAR.
Hematologic disorders. A number of studies have
documented that even in the elective setting, anemia or a
low hemoglobin level is associated with increased mortality
following OSR. Ho and colleagues12 documented that a
hemoglobin level of less than 10.5 g/dL was an indepen-
dent determinant of blood loss. A hematocrit less than 28%
has also been associated with an increased incidence of post-
operative MI in patients undergoing vascular surgery. There-
fore, we recommend perioperative blood transfusion if the
preoperative hematocrit is less than 28%. Ho et al have also
documented that a platelet count of 130,000 platelets/L or
less was associated with increased risk of bleeding among
patients undergoing OSR,12 and Matsumura and colleagues
noted that a lower preoperative platelet countwas an indepen-
dent predictor of two-year mortality among patients under-
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logic assessment is recommended if the preoperative platelet
count is less than 130,000 platelets/L.
Perioperative blood transfusion is recommended if the preoperative
hematocrit is 28%.
Level of recommendation: Weak
Quality of evidence: Low
Further hematologic assessment is recommended if the preoperative
platelet count is less than 130,000 platelets/L.
Level of recommendation: Weak
Quality of evidence: Low
Areas in Need of Further Research
● Perioperative management recommendations for patients with
preexistent anemia.
Genetic markers identifying risk of aortic aneu-
rysm. Genetic abnormalities associated with AAA, include
Ehlers-Danlos type IV (COL3A1), an autosomal dominant
defect in the type-III collagen synthesis. Isolated AAA, unre-
lated to a prior aortic dissection, is uncommonly associated
withMarfan syndrome. Population screening for single nucle-
otide polymorphisms (SNPs) to identify patients at risk for
AAA have identified a number of genetic variants proposed to
be associated with AAA, but few, if any, of these findings have
been reproduced in more than one independent research
group. A recent large study has suggested that a common
sequence variant on 9p21, rs10757278-G, is associatedwith a
31% increased risk of abdominal aortic aneurysm.14
Areas in Need of Further Research
● The genetic and molecular basis of familial AAA.
● Biomarkers and single nucleotide genetic polymorphisms that
identify patients at risk for development, progression, or rup-
ture of an AAA.
Aneurysm imaging
Image derived criteria to predict risk of AAA rup-
ture. MaximumAAAdiameter remains themost widespread
criterion to predict risk of AAA rupture, but a variety of
alternate parameters have been proposed as more sensitve
predictors of rupture risk including AAA expansion rate, in-
crease in intraluminal thrombus thickness, wall stiffness, wall
tension, and peak AAA wall stress.15 As an enlarging AAA is
accompanied both by an increase in wall stress and a decrease
in wall strength, recent efforts have also been directed to
accurately map the pointwise distribution of AAA wall stress
and strength as a more accurate determinant of rupture risk.
Further validation of these tools, however, will be required
before they can be applied with confidence in clinical practice.Areas in Need of Further Research
● Applicability of estimates of AAA tensile stress and wall
strength or other computed tomography (CT), magnetic reso-
nance imaging (MRI), or positron emission tomography
(PET) derived parameters to identify patients at risk for rapid
AAA growth or rupture.
Recommendations for aneurysm screening and sur-
veillance. Four randomized clinical trials that included
127,891 men and 9,342 women between the ages of 65 and
79 years have provided evidence that ultrasound screening is
effective in reducing AAA-related mortality.16-21 Thus, we
recommend one-time ultrasound screening for AAA for all
men at or older than age 65, or as early as age 55 for those
with a family history of AAA. Ultrasound screening should
also be performed for women at or older than age 65 who
have smoked or have a family history. If an AAA is identi-
fied, we recommend follow-up imaging at 12-month inter-
vals for patients with an AAA of 3.5 cm to 4.4 cm in
diamater and at six-month intervals for patients with an
AAA diameter between 4.5 cm and 5.4 cm. For other-
wise healthy patients, imaging is recommended at three-
year intervals for those between 3.0 cm and 3.4 cm in
diameter and at five-year intervals if the aortic diameter
measures between 2.6 cm and 2.9 cm. It bears noting
that these recommendations are based upon maximum
external aortic diameter.
One-time ultrasound screening for AAA is recommended for all
men at or older than 65 years. Screening men as early as 55 years
is appropriate for those with a family history of AAA.
Level of recommendation: Strong
Quality of evidence: High
One-time ultrasound screening for AAA is recommended for all
women at or older than 65 years with a family history of AAA or
who have smoked.
Level of recommendation: Strong
Quality of evidence: Moderate
Re-screening patients for AAA is not recommended if an initial
ultrasound scan performed on patients 65 years of age or older
demonstrates an aortic diameter of 2.6 cm.
Level of recommendation: Strong
Quality of evidence: Moderate
Surveillance imaging at 12-month intervals is recommended for
patients with an AAA of 3.5 cm to 4.4 cm in maximum diameter.
Level of recommendation: Strong
Quality of evidence: Low
Surveillance imaging at six-month intervals is recommended for
those patients with an AAA between 4.5 cm and 5.4 cm in
maximum diameter.
Level of recommendation: Strong
Quality of evidence: Low
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with an AAA between 3.0 cm and 3.4 cm in maximum diameter.
Level of recommendation: Strong
Quality of evidence: Low
Follow-up imaging at five year intervals is recommended for
patients whose maximum aortic diameter is between 2.6 cm and
2.9 cm.
Level of recommendation: Weak
Quality of evidence: Low
Areas in Need of Future Research
● Screening for AAA in women and minorities.
● Optimal methods for invitation to AAA screening, ease of ac-
cess to initial ultrasound and follow up, costs and workforce
needs, and methods for providing risk-benefit information to
individuals offered screening.
● Psychological effects of screening on patients and their part-
ners.
● Effectiveness of screening programs initiated outside of initial
screening centers.
● Frequency of imaging surveillance for specific AAA size groups
(3 cm to 4.0 cm, 4.0 cm to 4.4 cm, 4.5 cm to 4.9 cm, and 5.0
cm to 5.5 cm).
TREATMENT OF THE PATIENT WITH AN AAA
The decision to treat
Patients that present with an AAA and abdominal or back
pain, even of an atypical nature, are at increased risk of rupture
and intervention is recommended. For those who present
with an asymptomatic AAA,management is dependant on the
size of the aneurysm. There is general agreement that small
fusiform aneurysms, less than 4.0 cmmaximum diameter, are
at low risk of rupture and should bemonitored and a fusiform
aneurysm greater than 5.4 cm in maximum diameter should
be repaired in a healthy patient. Elective repair is also reason-
able for patients that present with a sacular aneurysm. Debate
remains for patients presenting with AAAs between 4.0 cm
and 5.4 cm regarding the most appropriate role for either
immediate treatment or surveillance and selective repair for
those aneurysms that subsequently enlarge beyond 5.4 cm.
Long-term survival was equivalent in the United Kingdom
Small Aneurysm Trial (UKSAT)22 and the Aneurysm Detec-
tion and Management (ADAM) Trial23 for both immediate
surgery and surveillance groups. Nonetheless, a trend towards
a beneficial effect of early surgery was observed in both studies
in the younger patient and for those with larger aneurysms.
Uncertainty regarding the potential benefit of early repair in
selected patients with small AAA is further magnified by the
demonstration that EVAR is associated with reduced
perioperative mortality. The Comparison of surveillance
vs endografting for small aneurysm repair (CAESAR)24 and
Positive impact of endovascular options for treating aneu-
rysm early (PIVOTAL) trials compare immediate EVAR
with surveillance and selective EVAR, but neither trial has
been designed to determine whether immediate EVARmight be beneficial or harmful for specific AAA size ranges
or age subgroups. Patients need to appreciate the therapeu-
tic uncertainty for AAA in the range of 4.0 cm to 5.4 cm. At
present, surveillance with selective repair is most appro-
priate for older male patients with significant co-mori-
bidities. Young, healthy patients, and especially women,
with AAA between 5.0 cm and 5.4 cm may benefit from
early repair.
Repair is recommended for patients that present with an AAA and
abdominal or back pain.
Level of recommendation: Strong
Quality of evidence: High
Elective repair is recommended for patients that present with a
fusiform AAA  5.5 cm in maximum diameter, in the absence
of significant co-morbidities.
Level of recommendation: Strong
Quality of evidence: High
Elective repair should be considered for patients that present with a
saccular aneurysm.
Level of recommendation: Weak
Quality of evidence: Low
Surveillance is recommended for most patients with a fusiform
AAA in the range of 4.0 cm to 5.4 cm in maximum diameter.
Level of recommendation: Strong
Quality of evidence: Moderate
Areas in Need of Further Research
● Management recommendations for EVAR versus surveil-
lance and selective treatment for AAA 5.5 cm.
● Examination of the survival effect of immediate treatment ver-
sus surveillance and selective treatment for specific AAA size
(4.0 cm to 4.4 cm, 4.5 cm to 4.9 cm, and 5.0 cm to 5.5 cm),
age, gender, and fitness subgroups.
● Scales of fitness for surgical or endovascular intervention.
● Management recommendations for AAA in women and
minorities.
Medical management during the period of AAA
surveillance
During the surveillance period, patients should be coun-
seled to cease smoking if tobacco products are being utilized
and encouraged to seek appropriate management for hyper-
tension, hyperlipidemia, diabetes, and other atherosclerotic
risk factors. A statin and angiotensin-converting enzyme
(ACE) inhibitor should be initiated given their broad poten-
tial benefits and acceptable safety profile. Insufficient data
exists to recommend use of doxycycline or roxithromycin.
Likewise, although animal studies have suggested that beta
blockade protects against aneurysm expansion and rupture,
the evidence in clinical trials has generally not supported this
view.25,26 Patients should be counseled that moderate physi-
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growth rate. Screening of family members should be recom-
mended.
Smoking cessation is recommended to reduce the risk of AAA
growth and rupture.
Level of recommendation: Strong
Quality of evidence: High
Statins may be considered to reduce the risk of AAA growth.
Level of recommendation: Weak
Quality of evidence: Low
Doxycycline, roxithromycin, ACE inhibitors, and angiotensin
receptor blockers are of uncertain benefit in reducing the risk of
AAA expansion and rupture.
Level of recommendation: Weak
Quality of evidence: Low
The use of beta blockers to reduce the risk of AAA expansion and
rupture is not recommended.
Level of recommendation: Strong
Quality of evidence: Moderate
Screening for AAA is recommended for first degree relatives of
patients presenting with an AAA.
Level of recommendation: Strong
Quality of evidence: High
Areas in Need of Further Research
● Therapeutic strategies directed at reduction in AAA growth
rate or rupture risk, including clarification of the potential role
of doxycycline, roxithromycin, and statin therapy in the pro-
gression of aneurysmal disease.
● Therapeutic strategies directed at regression of AAA size.
● Biomarkers and genetic polymorphisms that identify new ave-
nues for pharmacotherapy.
Open surgery
Because many infrarenal AAA with favorable neck
anatomy are currently repaired with endovascular stent
grafts, in contemporary practice, all vascular surgeons
recognize that the technical complexity and challenges
of OSR have increased since only aneurysms with adverse
neck anatomy not felt to be suitable for EVAR undergo
standard OSR. It is clear, therefore, that a vascular
surgeon should be familiar and experienced with both an
anterior transperitoneal (TP) and left-flank retroperito-
neal (RP) approaches, utilizing each as determined by
patient anatomy and clinical needs. Although advocates
of a RP approach claim various physiologic benefits,
including reductions in fluid losses, cardiac stress, post-
operative pulmonary complications, and severity of ileus,
randomized prospective studies have generated conflict-ing results.27,28 A RP approach is generally preferable for
patients with a “hostile abdomen” secondary to multiple
prior intra-abdominal operations, a history of irradia-
tion, or stoma, or for repair of inflammatory aneurysms
or AAA associated with a horseshoe kidney. Perhaps the
clearest indication for a RP approach is extension of
aneurysmal disease to the juxtarenal or visceral aortic
segment. Exposure and control of the aorta in this
region, as well as the left renal and visceral branches, are
facilitated by a left lateral RP approach and opening of
the left diaphragmatic crura.
A retroperitoneal approach should be considered for patients in
which aneurysmal disease extends to the juxtarenal and/or
visceral aortic segment, or in the presence of an inflammatory
aneurysm, horseshoe kidney or hostile abdomen.
Level of recommendation: Strong
Quality of evidence: Moderate
Division of the left renal vein may be considered to gain suprarenal
aortic exposure.
Level of recommendation: Strong
Quality of evidence: High
Aortic clamping. The proximal extent of aneurys-
mal disease and quality of the aorta at the anticipated
clamp site are best determined by careful examination of
a high-quality fine-cut abdominal CT scan, both with
and without contrast to allow accurate identification of
aortic wall calcification and the extent of atheromatous
debris and the length and diameter of the aneurysm
neck. If extensive calcification or intraluminal atheroma-
tous disease is noted, or the aneurysm extends very close
to the renal arteries, a decision to clamp at a higher level
becomes advisable to minimize the risk of atheromatous
embolization into the renal arteries or clamp injury to
the aortic wall. Although suprarenal clamping is associ-
ated with an increased risk of postoperative decrease in
renal function and overall adverse events, overall 30-day
mortality is comparable to those patients repaired with
infrarenal crossclamping.
It is usually recommended that the proximal clamp
be applied first, in order to minimize the occurrence of
atheromatous embolization. Irrespective of clamp loca-
tion and method, however, systemic heparinization (75-
100U/kg) is utilized by almost all vascular surgeons for
elective AAA repair. In the circumstances of a ruptured
aneurysm or other unusual situations, heparin may be
omitted, with vigorous flushing of the graft prior to
restoring blood flow, or limited amounts of heparinized
saline may be instilled directly into distal vessels after
placement of the proximal clamp. For patients with a
history of heparin-induced thrombocytopenia, a throm-
bin inhibitor (eg, Bivalirudin, Argatroban) is recom-
mended at the time of aortic clamping.
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the optimal site of proximal aortic clamping based upon the
extent of aneurysmal disease and quality of the aorta.
Level of recommendation: Strong
Quality of evidence: High
A transbrachial or transfemoral balloon for aortic control may be
considered prior to anesthetic induction for patients with a
ruptured aortic aneurysm.
Level of recommendation: Weak
Quality of evidence: Low
A thrombin inhibitor (eg, Bivalirudin, Argatroban) is
recommended at the time of aortic clamping for patients with a
history of heparin-induced thrombocytopenia.
Level of recommendation: Strong
Quality of evidence: Moderate
Type and configuration of the graft. Excellent pa-
tency and long-term results have been achieved with a
wide variety of prosthetic grafts utilized for open AAA
repair, with surgeon preference and cost the dominant
determinants in aortic graft choice. Aorto-aortic
“straight tube” grafts are generally regarded as prefera-
ble to bifurcated prostheses due to a shortened operative
time, reduced blood loss, and less need for dissection
with attendant risk of injury to adjacent structures such
as the ureter, iliac veins, or autonomic nerve networks. In
most series of elective open aortic graft repair, tube grafts
are utilized in 40% to 50% of cases. Certainly bifurcated
grafts are advisable if clinically significant concomitant
iliac aneurysms (2.0 cm to 2.4 cm) are present, which
may be present in 20% to 30% of patients with infrarenal
AAA.29 If coexistent symptomatic aortoiliac occlusive
disease exists with limiting claudication, both aneurys-
mal and obliterative disease can be corrected with an
aortobifemoral graft.
Straight tube grafts are recommended for OSR of AAA in the
absence of significant disease of the iliac arteries.
Level of recommendation: Strong
Quality of evidence: High
The proximal aortic anastomosis should be performed as close to the
renal arteries as possible.
Level of recommendation: Strong
Quality of evidence: High
It is recommended that all portions of an aortic graft should be
excluded from direct contact with the intestinal contents of the
peritoneal cavity.
Level of recommendation: Strong
Quality of evidence: HighMaintenance of pelvic circulation. Although multi-
factorial in origin, ligation of a patent inferior mesenteric
artery (IMA) is the most commonly noted risk factor for
development of colon ischemia in many series. Whether or
not to reimplant a patent IMA into the aortic graft remains
controversial. Some authors have recommended frequent
or even routine reimplantation of a patent IMA, but its
value has not been clearly established. A prospective ran-
domized trial examining this question found no statistically
significant reduction of perioperative colon ischemia with
reattachment and preservation, although the data did sug-
gest that older patients or those with increased intraopera-
tive blood loss might benefit from reimplantation.30 It
seems reasonable to conclude that IMA reimplantation
should be considered in the presence of associated celiac
or superior mesenteric artery (SMA) occlusive disease, an
enlarged meandering mesenteric artery, a history of prior
colon resection, inability to preserve hypogastric perfu-
sion, substantial blood loss or intraoperative hypoten-
sion, poor IMA backbleeding when graft open, poor
Doppler flow in colonic vessels, or should the colon
appear ischemic.
It has long been accepted as a basic principle of aortic
reconstruction that blood flow to at least one internal iliac
artery should be maintained. Failure to achieve this has
usually lead to erectile dysfunction, symptomatic hip and
buttock claudication, or occasionally colon ischemia, but-
tock necrosis, or spinal cord (cauda equina) ischemia.29
Recently, the necessity to preserve perfusion of a least one
hypogastric artery has been questioned as EVAR has be-
come more widely utilized. AlthoughMehta and associates
reported no mortality or significant morbidity in a series of
48 patients requiring interruption of flow to both hypogas-
tric arteries as part of endovascular (n  32) or open
surgical (n  16) repair of aortoiliac aneurysms;31 buttock
claudication was noted in 42% and new onset of erectile
dysfunction in 14%. Firm conclusions on this topic cannot
be reached with certainty at present, however, it seems
prudent to make every effort to preserve hypogastric perfu-
sion on at least one side.
Reimplantation of a patent inferior mesenteric artery (IMA)
should be considered under circumstances that suggest an
increased risk of colonic ischemia.
Level of recommendation: Strong
Quality of evidence: High
It is recommended that blood flow be preserved to at least one
hypogastric artery in the course of OSR or EVAR.
Level of recommendation: Strong
Quality of evidence: High
Timing of surgery. Documented rupture, particularly
with associated hypotension, demands immediate transfer to
the operating room as rapidly as possible. The timing of
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aneurysms remains more controversial. A patient with a
known AAA or pulsatile mass on abdominal exam who pre-
sents with acute onset of back or abdominal pain should
undergo an immediate contrast enhanced CT scan to deter-
mine if rupture has occurred. The timing of AAA repair for
those patients with symptomatic but unruptured aneurysms
represents a clinical dilemma. Many series have demonstrated
a significantly higher operative mortality for patients with
symptomatic but unruptured AAA who undergo emergent
open repair. The reason for such differences in outcome are
multifactorial, but include the fact that emergent surgical
repair is often carried out in less favorable circumstances
without the usual surgical and anesthesia personnel or at times
outside the typical workday. Similarly, some patientsmay benefit
from preoperative preparation or interventions. Thus, each clin-
ical situation must be approached individually and, in selected
circumstances, it may be prudent to delay emergent repair of
symptomatic but unruptured aneurysms for four to 24 hours
until optimal conditionsmay be achieved. If such an approach
is elected, blood should be available and the patient cared for
in an intensive care unit (ICU) setting prior to operation.
A related practical concern regarding timing of operation,
which frequently arises but for which there is little data relates
to scheduling of elective repair in asymptomatic patients with
large AAA. There is certainly no standard of care in regard to
the time period within which elective repair must be carried
out.While there is little advantage in delay, it is appropriate to
obtain pertinent preoperative studies in a timely fashion, par-
ticularly in older, high-risk individuals.On occasion, however,
rupture may occur during this interval. Although completely
unpredictable, it is recommended that risks and benefits of a
planned course of action be clearly communicated to the
patient and family.
Immediate repair is recommended for patients that present with
documented aneurysm rupture.
Level of recommendation: Strong
Quality of evidence: High
Should repair of a symptomatic AAA be delayed to optimize
associated medical conditions, it is recommended that a patient
be monitored in an ICU-setting and blood products be available.
Level of recommendation: Strong
Quality of evidence: High
Perioperative outcomes of open AAA repair. Over
the past two decades, mortality risk of elective infrarenal
AAA repair in referral-based single institution reports from
selected centers of excellence has ranged from 1% to
4%.32-34 In multiple population-based series, however, em-
ploying state-wide or nation-wide data bases, reported
perioperative mortality rates have generally been in the 4%
to 8% range even in contemporary experience.35 Compli-
cations after open AAA repair are observed in 15% to 30% ofpatients. Multiple reports have identified a strong relation-
ship between outcomes following AAA repair and both
hospital and individual surgeon case volume and experi-
ence.36 We recommend that OSR be best performed at
centers that have a documented in-hospital mortality of less
than 5% for elective repair.
Elective OSR for AAA should be performed at centers with a
documented in-hospital mortality of less than 5% for open repair
of infrarenal AAA.
Level of recommendation: Strong
Quality of evidence: High
Areas in Need of Further Research
● To identify whether OSR outcomes vary with respect to aneu-
rysm features, gender, ethnicity, or socioeconomic status.
● Studies of hospital and physician volume-OSR outcome rela-
tionship.
● Simulation training in OSR.
● Cost effectiveness strategies for OSR that include consider-
ations of time away from work for patients and family mem-
bers and disease-specific quality of life instruments.
Endovascular repair
Endovascular aortic aneurysm repair (EVAR) is pro-
gressively replacing OSR for the treatment of infrarenal
AAA and now accounts for more than half of all AAA
repairs. Moreover, since the introduction of EVAR, the
annual number of deaths from intact and ruptured AAA has
significantly decreased in the United States. This has coin-
cided with an increase in elective AAA repair after the
introduction of EVAR and a decrease in the diagnosis and
repair of ruptured AAA.37
Suprarenal and infrarenal fixation. Pooled results
from EVAR devices support the safety and efficacy for
endografts with infrarenal fixation. Likewise, several obser-
vational studies have reported the efficacy and safety of
suprarenal endograft fixation. Concerns have been raised
regarding the short- and long-term risks of renal or mesen-
teric artery embolization and occlusion after EVAR with
suprarenal endograft fixation. However, 50% and 87% of
endografts used in the Dutch Randomised Endovascular
Aneurysm Management (DREAM) and Endovascular an-
eurysm repair (EVAR) trials, respectively, were performed
with endografts that used suprarenal fixation and onrates of
renal dysfunction appear to be no different when compared
with those patients treated with devices that rely upon
infrarenal fixation.
Areas in Need of Further Research
● Long-term safety of endografts with suprarenal fixation.
Recommended management of the internal iliac
artery. Several studies have revealed that unilateral embo-
lization of the hypogastric artery (HA) can be performed
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concomitant unilateral HA embolization during EVAR has
been shown to be safe and effective, as compared with
staged procedures. Although buttock claudication and
erectile dysfunction occur in up to 40% of patients after
unilateral hypogastric artery embolization, these symptoms
tend to improve over time.38 Patients should be aware that
in at least one large series, buttock claudication persisted in
12% of unilateral and 11% of bilateral hypogastric artery
interruptions, whereas impotence occured in 9% of unilat-
eral and 13% of bilateral HA occlusions.39
Bilateral hypogastric artery occlusion with endograft
extension into both external iliac arteries is occasionally
required in patients at high-risk for OSR. Initial concerns
about life-threatening pelvic or colonic ischemia and neu-
rologic deficits may have been overestimated as several
recent reports suggest that such devastating complications
rarely occur. Technical considerations that may reduce the
incidence of adverse events when bilateral HA emboliza-
tion is required, include staging bilateral HA embolization,
embolization of the main trunk of the HA so as to preserve
pelvic collateral vessels, preserving collateral branches from
the common and deep femoral and external iliac arteries,
and maintaining adequate anticoagulation during these
procedures.
As an adjunct to EVAR, bilateral hypogastric artery occlusion may
be acceptable in certain anatomic situations for patients at high-
risk for OSR.
Level of recommendation: Strong
Quality of evidence: Moderate
Areas in Need of Further Resaerch
● Improvements in branched EVAR devices to maintain pelvic
perfusion.
Role of EVAR in patients requiring urgent or emer-
gent repair. In an effort to improve outcomes for patients
presenting with symptomatic or ruptured AAAs, the impact
of urgent or emergent EVAR has been recently evaluated.
Observational studies have revealed improved outcomes
after emergent EVAR for ruptured AAAs, but significant
selection bias and lack of uniform inclusion criteria and
reporting standards confounds these analyses.40 In this
regard, a recent industry-sponsored study of emergent
EVAR and OSR in 100 consecutive patients across 10
institutions in Europe failed to demonstrate improved in-
hospital (35% and 39%, respectively) or three-month mor-
tality (40% and 42%).41 Identical mortality rates (53%) were
also reported in a study of 32 patients randomized to EVAR
or OSR.42 Nonetheless, recent studies analyzing national
trends in the United States have observed that EVAR is
being used with increasing frequency in the emergency
management of ruptured AAA, with decreasing mortality.
Results in non-teaching centers and low volume institu-tions, however, were substantially worse than those in
teaching hospitals and high volume centers. Establishing a
protocol for urgent or emergent EVAR for ruptured AAAs
appears to be essential to obtain optimal results. In partic-
ular, “hypotensive hemostasis,” which refers to restricting
aggresive fluid resuscitation as long as the patient remains
conscious and systolic blood pressure exceeds 50 mmHg
to 70 mm Hg, appears to be beneficial. In hemodynam-
ically unstable patients that do not have a preoperative
CT scan, intraoperative angiography and intravascular
ultrasound may assist in device selection. Abdominal
compartment syndrome may occur after EVAR for rup-
tured AAAs among hemodynamically unstable patients
with a large retroperitoneal hematoma and diffuse vis-
ceral edema. Early recognition through measurement of
bladder pressure and surgical decompression are neces-
sary to improve survival.
Emergent EVAR should be considered for treatment of a ruptured
AAA, if anatomically feasible.
Level of recommendation: Strong
Quality of evidence: Moderate
Areas in Need of Further Research
● Effectiveness of EVAR for ruptured AAA.
Role of EVAR in high-risk and unfit patients for
open repair. A number of reports have documented that
EVAR can be performed with low rates of perioperative
mortality and morbidity in patients at high risk for OSR.
Nonetheless, the ability of EVAR to provide a survival
advantage for patients considered truly unfit for open repair
is uncertain.43 Although a number of preoperative risk
prediction methods have been reported, additional re-
search is needed to define objective criteria that identify
patients who are unfit for OSR and whose anticipated life
expectancy limits benefit from EVAR.
EVAR may be considered for high-risk patients unfit for surgical
repair.
Level of recommendation: Weak
Quality of evidence: Low
Areas in Need of Further Research
● Management recommendations for EVAR versus no in-
tevention in high-risk patients unfit for OSR with an
AAA  5.5 cm.
● Improvement in medical management of patients with large
AAA considered unfit for OSR.
Perioperative outcomes of elective EVAR. It would
seem to be axiomatic that EVAR, as a minimally invasive
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30-day mortality rates as compared to OSR. Indeed,
among nonrandomized but controlled trials, 30-day mor-
tality rates of less than 2% were reported among all FDA
pivotal study populations (AneuRx; Medtronic, Inc, Min-
neapolis, Minn [n  416] 1.7%;44 Excluder; W.L. Gore,
Inc, Flagstaff, Ariz [n  235] 1.3%;45 Zenith; Cook Med-
ical, Inc, Bloomington, Ind [n  352] 1.1%;46,47 Power-
link; Endologix, Inc, Irvine, Calif [n  192] 1%48). How-
ever, pooled trial data representing the OSR cohorts was
associated with a comparable 30-day mortality rate of 1.4%.
In an analysis of pooled trial data for patients considered at
high risk for OSR, 30-day mortality for patients treated by
EVAR or OSR was comparable (2.9% EVAR vs. 5.1% OSR,
P  .32).49 Among randomized, prospective trials, lower
mortality was observed among those patients treated by
EVAR. Specifically, in-hospital mortality rates in the
EVAR-1 trial and the DREAM trial were 1.7% and 1.2% for
EVAR and 6% and 4.6% for OSR, respectively.50,51 These
differences, however, did not achieve statistical significance
(P  .1). It is recommended that elective EVAR be per-
formed at centers that have a documented in-hospital mortal-
ity of less than 3% and a primary conversion rate toOSRof less
than 2%.
It is noteworthy that with rapid adoption of this tech-
nology in the United States, much lower mortality rates
have been reported for EVAR than OSR in analyses of large
statewide and multi-state population-based databases. In a
recent analysis of 45,000 propensity-score-matchedMedicare
beneficiaries, mortality was significantly lower after EVAR
(1.2% vs 4.8%; P  .001), with reduction in mortality most
pronounced for those of advanced age (80-84 years: 1.6% vs
7.2%;85 years: 2.7% vs 11.2%;P .001).52 Likewise,major
medical complications are lower after EVAR than OSR. It is
possible, however, that differences in outcome reflect the
inclusion of anatomically more complex aneurysms among
the cohort treated by OSR. It is noteworthy that disparities in
EVAR outcome have been identified between patients of
varying ethnicity and insurance type.
Despite the reduction in mortality and medical mor-
bidity that appears associated with EVAR, the incidence
of local vascular or device related complications, as well
as the 30-day re-intervention rate is greater after EVAR
than OSR. The DREAM trial demonstrated that a higher
incidence of local vascular or device related complica-
tions occurred after EVAR than OSR (16% vs. 9%).51
Similar findings have been reported in observational
studies with local or vascular complications occuring in
9% to 16% of patients after EVAR. The EVAR-1 trial
revealed that almost 75% more secondary interventions
were undertaken within 30 days of the procedure or
within the same admission after EVAR as compared with
OSR.50
The DREAM and EVAR-1 trials have provided mid-
term follow-up data at two and four years, respectively.53,54
The initial reduction in all-cause mortality observed after
EVAR was eliminated within one to two years with equiv-
alent overall survival in both treatment groups. Moreover,EVAR was associated with a greater number of late com-
plications and secondary reinterventions. A population-
based study of 45,660 Medicare beneficiaries undergoing
either EVAR or OSR demonstrates similar findings.52
Further research is needed to improve EVAR devices
and related techniques to reduce complications and long-
term follow-up; to identify whether EVAR outcomes vary
with respect to endograft type, aneurysm features, gender,
ethinicity, and socioeconomic status; and to define the
relationship of hospital and physician volume to outcomes
after EVAR.
EVAR should be performed at centers with documented in-hospital
mortality for elective EVAR of less than 3% and a perioperative
conversion rate to OSR of less than 2%.
Level of recommendation: Strong
Quality of evidence: High
Areas in Need of Further Research
● To identify whether EVAR outcomes vary with respect to en-
dograft type, aneurysm features, gender, ethnicity, or socio-
economic status.
● Studies of hospital and physician volume-EVAR outcome rela-
tionship.
● Simulation training in EVAR.
● Cost effectiveness strategies for EVAR that include consider-
ations of time away from work for patients and family mem-
bers and disease-specific quality of life instruments.
● Recommendations for staged or simultaneous EVAR and renal
angioplasty.
ANESTHETIC CONSIDERATIONS AND
PERIOPERATIVE MANAGEMENT
Intraoperative fluid resuscitation and blood
conservation
Intraoperative blood salvage during OSR can be
achieved using either red blood cells (RBC) processors
or hemofiltration devices. However, cell salvage tech-
niques during vascular surgery have not prevented the
need for transfusion and have not proven cost-effective.
Routine use of cell salvage and ultrafiltration devices
cannot be recommended, but is recommended if large
blood loss is anticipated.
The benefit of maintaining a hemoglobin of at least
10 gm/dL during OSR is unknown and randomized
trials have not been conducted to address this question.
It would seem prudent to have a lower threshold for
transfusion in the presence of ongoing blood loss, but
evidence is lacking. Likewise, optimal blood replacement
therapy during complex OSR has not been defined and
research in this area is encouraged.
Intravenous fluids for abdominal aortic surgery has
been the topic of many investigations over the past three
decades, however, there is no overwhelming evidence in
favor of the preferential use of any specific type of fluid or
fluid regimen. Moreover, there is no evidence of the
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loid and crystalloid. Although the cost of fluid is small, a
positive fluid balance after OSR may be predictive of
major adverse events, increased ICU and overall hospital
length of stay.
Preoperative autologous blood donation may be beneficial for
patients undergoing open aneurysm repair.
Level of recommendation: Weak
Quality of evidence: Moderate
Cell salvage or an ultrafiltration device is recommended if large
blood loss is anticipated or the risk of disease transmission from
banked blood considered high.
Level of recommendation: Strong
Quality of evidence: Weak
Intraoperative blood transfusion is recommended for a hematocrit
30% in the presence of ongoing blood loss.
Level of recommendation: Strong
Quality of evidence: Weak
If the intraoperative hematocrit is 30% and blood loss is ongoing,
resuscitation fluids should consider use of FFP and platelets in a
ratio with packed blood cells of 1:1:1.
Level of recommendation: Strong
Quality of evidence: Weak
Areas in Need of Further Research
● Recommendations for cell salvage and ultrafiltration devices
during OSR.
● Recommendations for intraoperative blood product-based resus-
citation during OSR.
● Recommendations for intraoperative fluid resuscitation during
OSR.
● Optimal use of ICU after OSR.
Intra- and postoperative cardiovascular monitoring
Clinical studies have not demonstrated altered out-
come from routine use of either a pulmonary artery
catheter, transesophageal echocardiography, ST-seg-
ment monitoring, or intravenous nitroglycerin. How-
ever, patients at increased risk of a cardiac event follow-
ing EVAR or OSR should be considered for
electrocardiogram (ECG) monitoring and measurement
of postoperative troponin levels, since troponin elevation
is predictive of adverse short- and long-term out-
comes.55,56 Otherwise, troponin measurement is only
recommended for patients with postoperative ECG
changes, chest pain, or other signs of cardiovascular
dysfunction. Overall, improved strategies to identify
postoperative patients at risk for MI are needed, and this
is an area recommended for further study.Pulmonary artery catheters should not be used routinely in aortic
surgery, unless there is a high risk for a major hemodynamic
disturbance.
Level of recommendation: Strong
Quality of evidence: High
Central venous access is recommended for all patients undergoing
open aneurysm repair.
Level of recommendation: Strong
Quality of evidence: High
Perioperative prophylaxis for deep vein thrombosis
It has been assumed that the risk of deep vein throm-
bosis (DVT) in patients undergoing vascular surgery with
systemic heparinization is low. However, DVT after open
AAA repair appears to be underappreciated. A Cochrane
analysis of all non-randomised prospective studies in aortic
surgery identified an average incidence of 9.2% among
patients without DVT prophylaxis.57 This incidence was
2.6% if calf DVT was excluded. Although a reduced risk
would be anticipated after EVAR, the incidence of femoral
or popliteal DVT after endovascular repair was 6% among
50 patients examined by Duplex ultrasonography.58 Con-
sistent with these findings, deMaistre et al59 recently re-
ported an incidence of lower extremity DVT of 10.2% after
OSR and 5.3% after EVAR (P  .28), despite prophylaxis
with thigh-length compression bandages or stockings, early
mobilization, and daily subcutaneous injection of low-molec-
ular-weight heparin beginning inmost patients within the first
day after OSR or EVAR. Indeed, aortic surgery may be
associatedwith a higher risk ofDVT than infrainguinal bypass.
Overall, most patients undergoing EVAR or OSR can
be considered at moderate to high risk for DVT, given
advanced age, duration of surgery 45 minutes, and the
increasing prevalence of obesity in the US population.
Therefore, DVT prophylaxis consisting of intermittent
pneumatic compression and early ambulation are recom-
mended for all patients undergoing OSR or EVAR. Pa-
tients at high risk (eg, prior history of DVT/pulmonary
embolism [PE], obesity [BMI 25], limited mobility sta-
tus, malignancy, hypercoaguable state) should receive ei-
ther low molecular weight heparin (LMWH) (enoxaparin
40 mg SQ once a day) or unfractionated heparin (5000 IU
SQ two or three times a day) initiated within 24 hours per
the judgement of the treating surgeon. If a high-risk patient
has a history of renal insufficiency, unfractionated heparin
(5000 IU SQ twice a day) is preferred, which is also favored
for those patients who have an epidural catheter.
DVT prophylaxis consisting of intermittent pneumatic compression
and early ambulation are recommended for all patients
undergoing OSR or EVAR.
Level of recommendation: Strong
Quality of evidence: High
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Level of recommendation: Strong
Quality of evidence: High
Areas in Need of Further Research
● Benefits of DVT prophylaxis and optimal prophylactic mea-
sures among patients undergoing OSR or EVAR.
POSTOPERATIVE AND LONG-TERM
MANAGEMENT
Late outcomes after open surgery and EVAR
Both EVAR and OSR are associated with late complica-
tions. Clinically significant complications appear to occur
more frequently after EVAR, but this technology continues to
evolve and newer endografts are associated with a lower inci-
dence of migration, disconnection and material fatigue.
Nonetheless, the incidence of certain procedure specific com-
plications, such as Type II endoleaks, remains unchanged.
Areas in Need of Further Resaerch
● Improvements in EVAR devices and related techniques to re-
duce complications and long-term follow-up.
Long-term complications related to the incision.
Retroperitoneal incisions for AAA repair have been associated
with weakened lateral abdominal wall musculature and a
bulge in up to 15% of patients. The more commonly used
laparotomy for transperitoneal AAA repair is, however, asso-
ciated with a higher incidence of late small bowel obstruction
and approximately one in five patients may develop a ventral
hernia, a finding, which appears to be substantially more
common after treatment of AAA than aortic occlusive disease.
Areas in Need of Further Research
● Strategies to reduce hernia formation and small bowel ob-
struction after OSR.
Para-anastomotic aneurysm. In one study of 511 pa-
tients, Kaplan-Meier analysis has shown a probability of
a para-anastomotic aneurysm of 0.8% at five years, 6.2% at 10
years, and 35.8% at 15 years.60 The likelihood that 15 years
after OSR 20% to 40% of patients may have a para-
anastomotic aneurysm has been confirmed by others, espe-
cially among those patients treated with an aortobifemoral
graft. Indolent graft infection should be suspected in all
pseudoaneurysms. Given the inability to precisely differentiate
anastomotic disruption from degenerative aneurysmal dilata-
tion, indications for repairing para-anastomotic aneurysms are
not well defined. Clearly large size and rapid enlargement are
indications for intervention. Redo OSR carries a significant
risk of major morbidity and mortality. Thus, the successfulapplication of endovascular repair when anatomically appro-
priate is a welcome approach to this difficult problem.
Graft infection. All implanted prostheses, whether
placed by OSR or EVAR, are at risk for infection either at
implantation or later by hematogenous seeding. This
complication is rare and represents about 0.3% of all
aortic operations. Graft infection, however, is the indi-
cation for intervention in up to 25% of redo aortic
surgery. The risk of graft infection after EVAR appears to
be similar to that of OSR. Primary aortic graft infection
usually presents late, on the average three years after
implantation and on occasion much later. Femoral ex-
tension of the abdominal grafts increases the incidence of
graft infection from 1% to nearly 3%. Presentations can
be quite diverse including generalized sepsis, groin pu-
rulence and drainage, pseudoaneurysm formation, or ill
defined pain. Staphylococcal organisms are the most
frequent bacterial isolates. Although the diagnosis may
be obvious, CT scanning usually provides the most in-
formation about the nature of the problem, extent of
infection, and other associated abnormalities. Angiogra-
phy may be required to plan therapy, especially if the
infection involves the femoral region precluding use of
the common femoral artery as an outflow for the
reconstruction.
Treatment traditionally includes excision of all in-
fected graft material with extra-anatomic reconstruction,
particularly in the presence of extensive contamination.
Outcome of treatment is poor with elevated mortality
and limb loss. Reiley demonstrated improved survival
after staging the procedure, starting with the extra-
anatomic reconstruction and in a separate procedure
performing the excision and debridement of the infected
field.61 In-situ reconstruction using femoral vein, silver
or antibiotic impregnated grafts, or arterial homografts,
have all been advocated as surgical options that may be
associated with reduced overall mortality in selected
patients with limited contamination.
Antibiotic prophylaxis of graft infection is required prior to
bronchoscopy, gastrointestinal or genitourinary endoscopy, and
any dental procedure that may lead to bleeding.
Level of recommendation: Strong
Quality of evidence: High
Generalized sepsis, groin drainage, pseudoaneurysm formation or
ill-defined pain after OSR or EVAR should prompt evaluation
of graft infection.
Level of recommendation: Strong
Quality of evidence: High
GI bleeding after OSR or EVAR should prompt evaluation of an
aortoenteric fistula.
Level of recommendation: Strong
Quality of evidence: High
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an omental flap and extra-anatomic reconstruction is
recommended for treatment of an infected graft in the presence
of extensive contamination.
Level of recommendation: Strong
Quality of evidence: High
In situ reconstruction with deep femoro-popliteal vein after graft
excision and debridement is a recommended option when
contamination is limited.
Level of recommendation: Strong
Quality of evidence: High
In situ reconstruction with silver or antibiotic impregnated grafts,
arterial homografts, or a PTFE graft may be considered in
patients with an infected prosthesis and limited contamination.
Level of recommendation: Weak
Quality of evidence: Low
Areas in Need of Further Research
● Infection-resistant aortic prostheses.
Limb occlusion. Nearly 25% of all arterial reinterven-
tions after OSR are due to limb occlusion, and are most
common in patients with associated occlusive disease. Limb
occlusion appears to be greater in women and in grafts
extending to the femoral artery. Isolated limb occlusion
usually presents with claudication, but occlusion of the
entire graft may present with severe ischemia. Endografts
are at a higher risk for limb thrombosis than prostheses
placed during the course of OSR, as observed in the
EVAR-1 trial.53 Endograft limbs, including stented limbs,
can be narrowed by a calcified small diameter aortic bifur-
cation or tortuous, angulated and diseased iliac arteries.
Treatment of an occluded limb after EVAR or OSR
includes thrombectomy or lytic therapy with secondary
endovascular or local surgical intervention, or extra-
anatomic bypass, such as femoral-femoral or axillo-femoral
bypass. Standard mechanical balloon thrombectomy may
be less successful with EVAR grafts because of sharp edges
produced by stents and concerns related to dislodging or
disrupting the sealing zones.
Follow-up of patients after EVAR or open surgery should include a
thorough lower extremity pulse exam or ankle-brachial index (ABI).
Level of recommendation: Strong
Quality of evidence: High
New onset of lower extremity claudication, ischemia, or a reduction
in ABI after OSR or EVAR should prompt an evaluation of
graft limb occlusion.
Level of recommendation: Strong
Quality of evidence: HighEndoleak. Endoleak, or persistent blood flow in the
aneurysm sac outside of the endograft, is the most frequent
complication after EVAR and has been reported in nearly one
in four patients at some time during follow-up. It is one of the
most common abnormalities identified on late imaging and
used to justify lifelong follow-up of these patients. Four types
of endoleak have been described, independent of graft type:
Type I endoleak occurs in the absence or loss of com-
plete sealing at the proximal (Type 1A) or distal (Type 1B)
end of the stent graft. Type I endoleak is associated with
significant pressure elevation in the sac and has been linked to
a continued risk of rupture. Every attempt should be made to
resolve Type I endoleaks noted at the time of EVAR before
the patient leaves the intervention suite. On occasion, small
persistent Type I endoleaks may be observed and if endovas-
cular interventionhas beenunsuccessful, the only alternative is
surgical conversion.
Type II endoleaks are the most common form of en-
doleak and arise from retrograde filling of the sac by lumbar
branches or the inferior mesenteric artery. For those detected
at the time of EVAR, further treatment is not indicated, since
spontaneous resolution is possible. When noted at follow-up,
many resolve spontaneously, but somemay persist. Endoleaks
arising from the inferior mesenteric artery are thought to
resolve less frequently than those from lumbar vessels andmay
be associated with a greater risk of sac expansion. Although
delayed AAA rupture secondary to a Type II endoleak has
been reported, it is rare and many patients with Type II
endoleaks are observed without treatment. A risk benefit
analysis of close follow-up versus early intervention should
take into consideration the age of the patient, size of the
aneurysm, the vessels involved, and the expected efficacy of
treatment. A definite subset of patients with Type II leaks will
demonstrate sac enlargement, an indication of elevated pres-
sure, and increased risk of rupture. Treatment of these Type II
endoleaks is recommended.
Obliteration of Type II endoleaks can be difficult.
Transarterial retrograde catheterization of the offending
branches with occlusion by coiling or other embolic agents
can be effective, but requires advanced endovascular skills.
Translumbar direct puncture of the aneurysm sac can also be
utilized successfully. The principle of treatment is to eliminate
the branches at their junction with the aneurysm. Laparo-
scopic ligation of the inferior mesenteric artery or lumbar
arteries is a third option for treatment of a Type II endoleak.
Type III endoleaks arise from poorly seated modular
connections, disconnection and separation of components,
or, infrequently, fabric erosion related to material fatigue. All
Type III endoleaks should be treated.
Type IV endoleaks represents self-limiting blood seep-
age through the graftmaterial due to porosity and treatment is
not required.
Type I endoleaks should be treated.
Level of recommendation: Strong
Quality of evidence: High
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AAA expansion.
Level of recommendation: Strong
Quality of evidence: Moderate
Treatment may be considered for Type II endoleaks not associated
with AAA enlargement.
Level of recommendation: Strong
Quality of evidence: Moderate
Type III endoleaks should be treated.
Level of recommendation: Strong
Quality of evidence: High
Type IV endoleaks do not require treatment.
Level of recommendation: Strong
Quality of evidence: Moderate
Conversion to OSR of an AAA is recommended if a Type I or III
endoleak does not resolve with endovascular treatment.
Level of recommendation: Strong
Quality of evidence: High
Conversion to OSR of an AAA is recommended for a Type II
endoleak in association with a large or expanding aneurysm that
does not resolve with endovascular or laparoscopic treatment.
Level of recommendation: Strong
Quality of evidence: High
Areas in Need of Further Research
● Management strategies for Type II endoleaks.
● Durability of EVAR after additional interventions for treat-
ment of Type I or III endoleak or device migration.
Endotension. An AAA may continue to enlarge after
endovascular repair, even in the absence of a detectable en-
doleak, and this enlargement may lead to aneurysm rupture.
Explanations for persistent or recurrent pressurization of an
aneurysm sac include blood flow that is below the sensitivity
limits for detection with current imaging technology or pres-
sure transmission through thrombus or endograft fabric. Ad-
ditionally, a serous ultrafiltrate across amicroporous fabric can
fill the aneurysm and increase pressure. Since sources of endo-
tension can be difficult to detect, treatment strategies must be
individualized. Relining devices with low porosity alternatives
may abolish sac growth or induce shrinkage of the sac. On
occasion, explantation and conversion may be required when
no clear cause can be detected and endoleak, as a cause of sac
expansion, cannot be excluded.
Treatment of endotension to prevent aneurysm rupture is suggested
in selected patients with continued aneurysm expansion.
Level of recommendation: Weak
Quality of evidence: LowDevice migration. Device migration after EVAR is
multi-factorial and can be asymptomatic. It is normally
detected on CT scan by the presence of a Type I en-
doleak and can lead to repressurization of the aneurysm
sac and rupture. Although cranial migration of distal iliac
attachment can occur and may have a similar effect in
pressurizing the aneurysm sac, the most common form is
caudal migration of the proximal aortic neck attachment
site. The incidence of postoperative device migration
appears related to the duration of follow-up. Most series
evaluating device migration have reported increases after
24 months.
Recommendation for postoperative surveillance
The primary goal of AAA treatment is to prevent rup-
ture. As opposed to EVAR, OSR is not associated with a
risk of persistent sac enlargement, but may be associated
with late paranastomotic aneurysm formation or graft in-
fection. Although the later event is rare, late aneurysm
formation may be noted in approximately 1%, 5%, and 20%
of patients at five, 10, and 15 years after OSR, respectively.
Thus, we recommend follow-up CT imaging at five year
intervals after OSR.
Protocols for EVAR surveillance established as an out-
growth of initial FDA sponsored pivotal trials consist of CT
imaging at one, six, and 12 months after initial repair and
yearly thereafter. However, the frequent use of CT scan-
ning has raised concerns related to the added costs of these
studies, as well as cumulative radiation exposure and poten-
tial lifetime cancer risk.62 Although ultrasound avoids radi-
ation exposure and use of nephrotoxic contrast agents,
concerns have been raised in the past regarding the variable
sensitivity of ultrasound in identifying endoleaks. Recent
studies, however, have suggested that the lower sensitivity
of color Doppler ultrasound (CDU) as compared to CT
imaging is offset by a high degree of correlation between
CDU and CT imaging in detection of clinically significant
endoleaks.63 Moreover, recent small studies evaluating the
role of contrast-enhanced ultrasound in the detection of
endoleaks report increased sensitivity, negative predictive
value, accuracy, and specificity when compared with CDU.
The utility of ultrasound is primarily limited in obese pa-
tients or those presenting with substantial bowel gas or a
large ventral hernia.
Based on these recent reports, some investigators have
suggested that follow-up with CDU as the sole imaging
modality is appropriate, if neither an endoleak nor AAA
enlargement is documented on the first annual CT scan.64
A significant increase in aneurysm size or new onset of
endoleak, if detected by CDU at later follow-up, would
prompt CT imaging. Eliminating the traditional six-month
CT scan has also been recommended, if CT imaging one
month after EVAR does not identify an endoleak.64,65
Further research is needed to confirm the broader efficacy
of these modified protocols. It should also be noted that
while risk for endoleak declines as the number of negative
postoperative scans increases, new endoleaks may be iden-
tified as late as seven years following EVAR. Convention
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aneurysm enlargement, should be followed with CT imag-
ing at six-month intervals. However, Type II endoleaks in
the presence of a shrinking or small stable aneurysm are
characterized by a relatively benign natural history in most
cases. Thus, further studies may demonstrate that CDU at
six or even 12-month intervals may be a reasonable alter-
native, especially for patients whose aneurysms are less than
6.5 cm in diameter.
The Acute pressure measurement to confirm aneurysm
exclusion (APEX) trial confirmed that intrasac pressure and
pressure changes could be reliably measured non-invasively
by a pressure sensor.66 As an alternative to postoperative
CT imaging, algorithms to identify a significant endoleak
based on pressure changes are under evaluation.
We currently recommend contrast enhanced CT imag-
ing one and 12 months during the first year after EVAR.
Should CT imaging at one month after EVAR identify an
endoleak or other abnormality of concern, postoperative
imaging at six months should be added to further evaluate
the proper exclusion of the aneurysm. If neither an en-
doleak nor aneurysm enlargement is documented during
the first year after EVAR, Color Duplex ultrasonography
may be a reasonable alternative to CT imaging for postop-
erative surveillance. However, these studies should be per-
formed by a skilled technician in an accredited non-invasive
vascular laboratory. Likewise, follow-up with CDU and
non-contrast CT imaging is reasonable for patients with
renal insufficiency at any time after EVAR. The presence of
a Type II endoleak should initially prompt continued CT
surveillance to ascertain whether the aneurysm is increasing
in size. If the aneurysm is shrinking or stable in size,
follow-up with CDU may be a reasonable alternative to
continued CT imaging. Detection of a new endoleak after
prior imaging studies have suggested complete aneurysm
sac exclusion should prompt evaluation for a Type I or Type
III endoleak. Given the risk of paraanastomotic aneurysm,
non-contrast CT imaging at five-year intervals is recom-
mended for patients after OSR.
Surveillance during the first year after EVAR should consist of
contrast enhanced CT imaging at one and 12 months.
Level of recommendation: Strong
Quality of evidence: High
If a Type II endoleak or other abnormality of concern is observed on
contrast enhanced CT imaging at one month after EVAR,
postoperative imaging at six months is recommended.
Level of recommendation: Strong
Quality of evidence: High
If neither endoleak nor AAA enlargement is documented during
first year after EVAR, Color Duplex ultrasonography is suggested
as an alternative to CT imaging for annual postoperative
surveillance.
Level of recommendation: Weak
Quality of evidence: LowThe presence of a type II endoleak should initially prompt continued
CT surveillance to ascertain whether the aneurysm is increasing
in size. If the aneurysm is shrinking or stable in size, follow-up
with CDU is suggested as an alternative to continued CT
imaging.
Level of recommendation: Weak
Quality of evidence: Low
A new endoleak that is detected after prior imaging studies have
suggested complete aneurysm sac exclusion should prompt
evaluation for a Type I or Type III endoleak.
Level of recommendation: Strong
Quality of evidence: High
Color Duplex ultrasonography and a non-contrast CT scan are
recommended as a substitute for contrast enhanced CT imaging
for post-EVAR surveillance of patients with renal insufficiency.
Level of recommendation: Strong
Quality of evidence: High
Non-contrast CT imaging of the entire aorta is recommended at
five year intervals after OSR or EVAR.
Level of recommendation: Strong
Quality of evidence: High
Areas in Need for Further Research
● Postoperative surveillance protocols, including optimal use of
CDU, contrast enhanced CDU, and CT imaging at various
time periods after OSR or EVAR (0-5, 5-10, 10-15 years).
● Effectiveness of pressure sensors in reduction of postoperative
surveillance costs.
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